Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 28, 2003. The document serves as a notification of the publication of the company's 2002 Annual Report, Annual Review, and Corporate Social Responsibility Report. It also includes the Chairman's letter to shareholders and the Notice of the Annual General Meeting (AGM) scheduled for May 19, 2003. The filing highlights the completion of GSK's second financial year following the merger of Glaxo Wellcome and SmithKline Beecham.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the 2002 fiscal year, referring instead to the enclosed Annual Report for detailed financial statements. However, the following financial data points are explicitly stated:
- Share Price Performance: GSK shares declined 37% from the start of 2001 to the end of 2002, a decline in line with the FTSE 100 and the peer group average.
- Share Repurchase: On March 27, 2003, the company purchased 850,000 ordinary shares for cancellation at a price of 1,167.83p per share.
- Outstanding Options: As of March 3, 2003, approximately 242 million options to subscribe for ordinary shares were outstanding, representing 4.01% of issued share capital.
- Capital Structure: The US market represents 54% of revenues.
Material Changes and Operational Highlights
The Chairman's letter outlines several material developments and strategic positions:
- Merger Integration: Management has exceeded cost savings targets in both amount and speed. The company has signed 24 major external collaborations over the two years since the merger.
- Product Performance: 'Seretide/Advair' has become GSK's number one product in Europe and the market leader in the US asthma market.
- Developing World Initiatives: Shipments of the core antiretroviral medicine 'Combivir' to the developing world increased tenfold between Q1 2001 and Q4 2002. The company offers ARVs at not-for-profit preferential prices to Least Developed Countries and Sub-Saharan Africa.
- Market Environment: The company faced a hostile pharmaceutical environment characterized by generic competition, price pressures, and regulatory challenges.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Chairman emphasizes that while share prices are influenced by macroeconomic factors, the company remains "alive and well" and is meeting its social obligations. The Board intends to monitor competitor remuneration trends closely to ensure GSK remains competitive in retaining top management talent, though no immediate adjustments to long-term incentive awards were made following adverse publicity in the UK.
Risks and Contingencies:
- Remuneration Disparity: Significant differences between UK and US cultural attitudes toward executive pay threaten the company's ability to compete for talent globally. GSK is currently behind competitors in long-term incentive awards.
- Corporate Governance: The dual UK/US headquarters structure exposes the company to differing views on governance and remuneration.
- Regulatory Changes: The company is monitoring proposed UK regulations regarding the holding of treasury shares, which could impact capital management flexibility.
Investor Verification Checklist
- Verify the full 2002 financial statements (revenue, profit, cash flow) in the separate Annual Report, as this filing only references them.
- Review the Remuneration Report to understand the specific gap between GSK's executive pay and industry competitors.
- Confirm the status of the 24 major external collaborations mentioned and their contribution to the product pipeline.
- Monitor the outcome of the AGM resolutions regarding the disapplication of pre-emption rights and the authority to purchase up to 600 million own shares.
- Assess the impact of the 37% share price decline on employee wealth and retention strategies.